Titre : Optogénétique

Optogénétique : Questions médicales fréquentes

Termes MeSH sélectionnés :

CADASIL
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Optogénétique : Questions médicales les plus fréquentes", "headline": "Optogénétique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Optogénétique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-26", "dateModified": "2025-04-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Optogénétique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Techniques génétiques", "url": "https://questionsmedicales.fr/mesh/D005821", "about": { "@type": "MedicalCondition", "name": "Techniques génétiques", "code": { "@type": "MedicalCode", "code": "D005821", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E05.393" } } }, "about": { "@type": "MedicalCondition", "name": "Optogénétique", "alternateName": "Optogenetics", "code": { "@type": "MedicalCode", "code": "D062308", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Zachary P Harmer", "url": "https://questionsmedicales.fr/author/Zachary%20P%20Harmer", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States." } }, { "@type": "Person", "name": "Megan N McClean", "url": "https://questionsmedicales.fr/author/Megan%20N%20McClean", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States." } }, { "@type": "Person", "name": "Yubin Zhou", "url": "https://questionsmedicales.fr/author/Yubin%20Zhou", "affiliation": { "@type": "Organization", "name": "Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA." } }, { "@type": "Person", "name": "Tobias Bruegmann", "url": "https://questionsmedicales.fr/author/Tobias%20Bruegmann", "affiliation": { "@type": "Organization", "name": "Institute of Physiology I, Medical Faculty, University of Bonn, 53127, Bonn, Germany." } }, { "@type": "Person", "name": "Daniela Malan", "url": "https://questionsmedicales.fr/author/Daniela%20Malan", "affiliation": { "@type": "Organization", "name": "Institute of Physiology I, Medical Faculty, University of Bonn, 53127, Bonn, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "ER stress induced immunopathology involving complement in CADASIL: implications for therapeutics.", "datePublished": "2023-05-08", "url": "https://questionsmedicales.fr/article/37158955", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s40478-023-01558-1" } }, { "@type": "ScholarlyArticle", "name": "Sex differences in frontotemporal atrophy in CADASIL revealed by 7-Tesla MRI.", "datePublished": "2022-12-21", "url": "https://questionsmedicales.fr/article/36577270", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2022.103298" } }, { "@type": "ScholarlyArticle", "name": "Exonic mutations in cell-cell adhesion may contribute to CADASIL-related CSVD pathology.", "datePublished": "2023-07-08", "url": "https://questionsmedicales.fr/article/37422595", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00439-023-02584-8" } }, { "@type": "ScholarlyArticle", "name": "Clinical and epidemiological profiles from a case series of 26 Brazilian CADASIL patients.", "datePublished": "2023-05-08", "url": "https://questionsmedicales.fr/article/37156532", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0042-1758756" } }, { "@type": "ScholarlyArticle", "name": "CADASIL Affects Multiple Aspects of Cerebral Small Vessel Function on 7T-MRI.", "datePublished": "2022-11-01", "url": "https://questionsmedicales.fr/article/36222455", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ana.26527" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Techniques d'investigation", "item": "https://questionsmedicales.fr/mesh/D008919" }, { "@type": "ListItem", "position": 3, "name": "Techniques génétiques", "item": "https://questionsmedicales.fr/mesh/D005821" }, { "@type": "ListItem", "position": 4, "name": "Optogénétique", "item": "https://questionsmedicales.fr/mesh/D062308" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Optogénétique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Optogénétique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Optogénétique", "description": "Comment l'optogénétique est-elle diagnostiquée ?\nQuels outils sont utilisés pour le diagnostic ?\nPeut-on diagnostiquer des troubles avec l'optogénétique ?\nL'optogénétique nécessite-t-elle des échantillons biologiques ?\nQuels types de cellules sont ciblées en optogénétique ?", "url": "https://questionsmedicales.fr/mesh/D062308?mesh_terms=CADASIL&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Optogénétique", "description": "Quels symptômes l'optogénétique peut-elle aider à étudier ?\nL'optogénétique peut-elle induire des symptômes ?\nComment l'optogénétique aide-t-elle à comprendre les symptômes ?\nPeut-on mesurer des symptômes en temps réel ?\nQuels symptômes sont liés aux troubles traités par l'optogénétique ?", "url": "https://questionsmedicales.fr/mesh/D062308?mesh_terms=CADASIL&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Optogénétique", "description": "L'optogénétique peut-elle aider à prévenir des maladies ?\nComment l'optogénétique contribue-t-elle à la recherche préventive ?\nPeut-on utiliser l'optogénétique pour des études épidémiologiques ?\nQuels types de prévention sont envisagés avec l'optogénétique ?\nL'optogénétique peut-elle aider à identifier des biomarqueurs ?", "url": "https://questionsmedicales.fr/mesh/D062308?mesh_terms=CADASIL&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Optogénétique", "description": "L'optogénétique est-elle utilisée comme traitement ?\nQuels types de maladies pourraient bénéficier de l'optogénétique ?\nComment l'optogénétique est-elle administrée ?\nQuels sont les résultats attendus des traitements optogénétiques ?\nY a-t-il des effets secondaires connus ?", "url": "https://questionsmedicales.fr/mesh/D062308?mesh_terms=CADASIL&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Optogénétique", "description": "Quelles complications peuvent survenir avec l'optogénétique ?\nY a-t-il des risques associés à l'optogénétique ?\nComment minimiser les complications en optogénétique ?\nLes complications sont-elles fréquentes ?\nQuelles sont les complications à long terme ?", "url": "https://questionsmedicales.fr/mesh/D062308?mesh_terms=CADASIL&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Optogénétique", "description": "Quels sont les facteurs de risque pour l'optogénétique ?\nL'âge influence-t-il les résultats de l'optogénétique ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes facteurs génétiques jouent-ils un rôle ?\nComment évaluer les facteurs de risque en optogénétique ?", "url": "https://questionsmedicales.fr/mesh/D062308?mesh_terms=CADASIL&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment l'optogénétique est-elle diagnostiquée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle est diagnostiquée par des techniques d'imagerie et des tests fonctionnels sur des cellules modifiées." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des microscopes à fluorescence et des systèmes de stimulation lumineuse sont utilisés." } }, { "@type": "Question", "name": "Peut-on diagnostiquer des troubles avec l'optogénétique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à étudier des troubles neurologiques en ciblant des neurones spécifiques." } }, { "@type": "Question", "name": "L'optogénétique nécessite-t-elle des échantillons biologiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des échantillons de tissus ou de cellules sont souvent nécessaires pour l'analyse." } }, { "@type": "Question", "name": "Quels types de cellules sont ciblées en optogénétique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Principalement des neurones, mais aussi d'autres types cellulaires peuvent être modifiés." } }, { "@type": "Question", "name": "Quels symptômes l'optogénétique peut-elle aider à étudier ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle aide à étudier des symptômes comme l'anxiété, la dépression et les troubles moteurs." } }, { "@type": "Question", "name": "L'optogénétique peut-elle induire des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle ne provoque pas de symptômes, mais elle permet d'observer des réponses neuronales." } }, { "@type": "Question", "name": "Comment l'optogénétique aide-t-elle à comprendre les symptômes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de manipuler des circuits neuronaux pour observer les effets sur le comportement." } }, { "@type": "Question", "name": "Peut-on mesurer des symptômes en temps réel ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'optogénétique permet des mesures en temps réel des réponses neuronales aux stimuli." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux troubles traités par l'optogénétique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme les convulsions, les troubles de l'humeur et les déficits cognitifs." } }, { "@type": "Question", "name": "L'optogénétique peut-elle aider à prévenir des maladies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, en permettant une meilleure compréhension des mécanismes de la maladie." } }, { "@type": "Question", "name": "Comment l'optogénétique contribue-t-elle à la recherche préventive ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'étudier les facteurs de risque et les mécanismes sous-jacents des maladies." } }, { "@type": "Question", "name": "Peut-on utiliser l'optogénétique pour des études épidémiologiques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être intégrée dans des études pour comprendre la propagation des maladies." } }, { "@type": "Question", "name": "Quels types de prévention sont envisagés avec l'optogénétique ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des stratégies de prévention basées sur la modulation des circuits neuronaux." } }, { "@type": "Question", "name": "L'optogénétique peut-elle aider à identifier des biomarqueurs ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut aider à identifier des biomarqueurs pour des maladies neurologiques." } }, { "@type": "Question", "name": "L'optogénétique est-elle utilisée comme traitement ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle est principalement utilisée pour la recherche, mais a un potentiel thérapeutique." } }, { "@type": "Question", "name": "Quels types de maladies pourraient bénéficier de l'optogénétique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies comme la maladie de Parkinson, l'épilepsie et les troubles de l'humeur." } }, { "@type": "Question", "name": "Comment l'optogénétique est-elle administrée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Elle est administrée par l'insertion de gènes sensibles à la lumière dans des cellules cibles." } }, { "@type": "Question", "name": "Quels sont les résultats attendus des traitements optogénétiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Amélioration des symptômes neurologiques et modulation des circuits neuronaux." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires connus ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont encore à l'étude, mais peuvent inclure des réponses immunitaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'optogénétique ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des infections ou des réactions aux vecteurs utilisés." } }, { "@type": "Question", "name": "Y a-t-il des risques associés à l'optogénétique ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des effets indésirables liés à la manipulation génétique." } }, { "@type": "Question", "name": "Comment minimiser les complications en optogénétique ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "En suivant des protocoles stricts et en surveillant les patients après les interventions." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont rares, mais la recherche continue d'évaluer la sécurité de la technique." } }, { "@type": "Question", "name": "Quelles sont les complications à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications à long terme sont encore mal comprises et nécessitent des études approfondies." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'optogénétique ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents médicaux, des maladies neurologiques et des traitements antérieurs." } }, { "@type": "Question", "name": "L'âge influence-t-il les résultats de l'optogénétique ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge peut affecter la réponse aux traitements optogénétiques et la récupération." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme le stress et l'exposition à des toxines peuvent influencer les résultats." } }, { "@type": "Question", "name": "Les facteurs génétiques jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les variations génétiques peuvent influencer la réponse aux interventions optogénétiques." } }, { "@type": "Question", "name": "Comment évaluer les facteurs de risque en optogénétique ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Par des évaluations cliniques et des études génétiques pour identifier les vulnérabilités." } } ] } ] }

Sources (103 au total)

Clinical and epidemiological profiles from a case series of 26 Brazilian CADASIL patients.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a genetic cause of ischemic stroke and the most common form of non-atherosclerotic stroke. Despi... We performed a case series study comprising 6 rehabilitation hospitals in Brazil and reported the clinical and epidemiological data from the medical records of patients admitted from 2002 to 2019 with... We enrolled 26 (16 female) patients in whom mutations in exons 4 and 19 were the most common. The mean age at the onset of the disease was of 45 years. Ischemic stroke was the first cardinal symptom i... The present is the most extensive series of Brazilian CADASIL patients published to date, and we have reported the first case of microbleeds in the spinal cord of a CADASIL patient. Most of our clinic...

CADASIL Affects Multiple Aspects of Cerebral Small Vessel Function on 7T-MRI.

Cerebral small vessel diseases (cSVDs) are a major cause of stroke and dementia. We used cutting-edge 7T-MRI techniques in patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infar... We recruited 23 CADASIL patients (age 51.1 ± 10.1 years, 52% women) and 13 age- and sex-matched controls (46.1 ± 12.6, 46% women). Small vessel function measures included: basal ganglia and centrum se... Compared with controls, CADASIL patients showed lower blood flow velocity and higher pulsatility index within perforating arteries of the centrum semiovale (mean difference - 0.09 cm/s, p = 0.03 and 0... Multiple aspects of cerebral small vessel function on 7T-MRI were abnormal in CADASIL patients, indicative of increased arteriolar stiffness and regional abnormalities in reactivity, locally also in r...

Novel mutations in HTRA1-related cerebral small vessel disease and comparison with CADASIL.

There is evidence showing both heterozygous HTRA1 and homozygous HTRA1 mutations as causal for familial cerebral small vessel disease (CSVD). The clinical and neuroimaging signs of heterozygous HTRA1-... We carried out genetic sequencing in a series of unrelated patients with suspected familial CSVD from China. Clinical and imaging characteristics of heterozygous HTRA1-related CSVD and CADASIL were co... We identified nine heterozygous HTRA1 mutations and one homozygous HTRA1 mutation, seven of which are novel. Compared with CADASIL, patients with heterozygous HTRA1-related CSVD had a higher proportio... This study shows that most HTRA1-related CSVD patients in China carry heterozygous HTRA1 mutations. The specific extra-neurological features and neuroimaging features reveal informative differences be...

White Matter Tract Injury by MRI in CADASIL Patients is Associated With Iron Accumulation.

Widespread white matter (WM) injury is a hallmark feature of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). However, controversies about the mech... To test the association between iron accumulation and WM tract injury in CADASIL patients.... Retrospective.... A total of 35 CADASIL patients (age = 50.4 ± 6.4, 62.9% female) and 48 healthy controls (age = 55.7 ± 8.0, 68.8% female).... Diffusion-weighted spin-echo echo-planar sequence; enhanced susceptibility-weighted angiography (ESWAN) gradient echo sequence on a 3 T scanner.... The phase images acquired by ESWAN were used to calculate quantitative susceptibility mapping (QSM). Iron accumulation was evaluated in deep gray matters using QSM. WM tract injury was quantified by d... General linear model (GLM), partial correlation, stepwise linear regression and mediation analysis were used. The threshold of statistical significance was set as p < 0.05.... Compared with healthy controls, CADASIL patients had significantly increased iron deposition in the caudate and putamen. Aberrant iron deposition in these two regions was significantly associated with... Patients with CADASIL show increased iron deposition in the caudate and putamen that is correlated to WM tract injury, which may in turn mediate the association with cognitive impairment.... 2 TECHNICAL EFFICACY: Stage 2....

The CADA-MRIT: An MRI Inventory Tool for Evaluating Cerebral Lesions in CADASIL Across Cohorts.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most frequent genetic cerebrovascular disease. The clinical aspects of the disease in relati... The Inventory Tool (CADA-MRIT) was designed by consensus after repeated expert meetings. It consists of 11 imaging items to assess periventricular, deep, and superficial white matter hyperintensity (W... Imaging data from 671 patients with CADASIL (440 from France, 119 from Germany, and 112 from Taiwan) were analyzed. Their mean age was 53.4 ± 12.2 years, 54.5% were women, 56.2% had stroke, and 31.1% ... The CADA-MRIT is an easy-to-use tool for analyzing and comparing the most frequent MRI lesions of CADASIL across different populations. This instrument is reliable. It can be used with different imagi...

A novel report of Cys1298Gly mutation in exon 24 of NOTCH3 gene in a Chinese family with CADASIL.

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common monogenic hereditary small cerebral vessel disease, which is caused by mutation ... We present a patient with clinical manifestations, laboratory examination and imaging reveal suspicion of CADASIL. The family and genetic test and pathological examination were performed.... Magnetic resonance imaging revealed diffuse leukoencephalopathy with hyperintense signals in the bilateral temporal poles, periventricular white matter, centrum semiovale, basal ganglia, frontal and p... To the best of our knowledge, this is the second case of exon 24 mutations reported from China and the variant of c.3892 T >G (p. Cys1298Gly) on exon 24 of NOTCH3 has not been reported so far. Our rep...